- Current languageen
Pharmaceuticals - Community Register
Community register of veterinary medicinal products
|Invented name:||Vectra 3D|
|Auth. number :||EU/2/13/156|
|Active substance :||dinotefuran, pyriproxyfen, permethrin|
|ATC:||Anatomical main group: QP - Antiparasitic products, insecticides and repellents|
Therapeutic subgroup: QP53 - Ectoparaciticides, insecticides and repellents
Pharmacological subgroup: QP53A - Ectoparasiticides for topical use, incl. insecticides
Chemical subgroup: QP53AC - Pyrethrins and pyrethroids
Chemical substance: QP53AC54 - permethrin, combinations
(See WHO ATCvet Index)
|Indication:||Fleas:Treatment and prevention of flea infestation (Ctenocephalides felis and Ctenocephalides canis). The treatment prevents flea infestation for one month. It also prevents multiplication of fleas for two months after application by inhibiting egg hatching (ovicidal activity) and by inhibiting the emergence of adults from eggs laid by adult fleas (larvicidal activity).|
The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Ticks:The veterinary medicinal product has persistent acaricidal and repellent efficacy against tick infestations (Rhipicephalus sanguineus and Ixodes ricinus for one month, and Dermacentor reticulatus for up to three weeks).
If ticks are present when the veterinary medicinal product is applied, the ticks may not all be killed within the first 48 hours, but they may be killed within a week. To removal ticks it is recommended to use an appropriate tick removal device.
Sand flies, mosquitoes and stable flies:The treatment provides persistent repellent (anti-feeding) activity. It prevents biting from sand flies (Phlebotomus perniciosus), mosquitoes (Culex pipiens, Aedes aegypti) and from stable flies (Stomoxys calcitrans) for one month post-application. The treatment also provides persistent insecticidal activity for one month against mosquitoes (Aedes aegypti) and stable fly (Stomoxys calcitrans).
|Marketing Authorisation Holder:||Ceva Santé Animale
10 avenue de la Ballastière, 33500 Libourne, France
|EPAR and active package presentations|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".|
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.
|Close date procedure||Procedure type||EMEA number||Decision||summary publ||decision docs||annex|
|06/12/2013||Centralised - Authorisation||EMEA/V/C/2555||(2013)8903 of 04/12/2013|
|03/11/2014||Corrigendum||(2013)8903 cor of 04/12/2013|
|20/02/2015||Centralised - Variation||EMEA/V/C/2555/IA/4/G|
|Updated with Decision(2016)1318 of 25/02/2016|
|19/02/2016||Centralised - Variation||EMEA/V/C/2555/IB/6|
|Updated with Decision(2017)1290 of 17/02/2017|
|29/02/2016||Centralised - Yearly update||(2016)1318 of 25/02/2016|
|21/02/2017||Centralised - Yearly update||(2017)1290 of 17/02/2017|